Today's Research Report Coverage on Medical Equipment Stocks -- Lantheus, Intersect ENT, CHF Solutions, and ReWalk Robotics

NEW YORK, August 25, 2017 /PRNewswire/ --

If you want a Stock Review on LNTH, XENT, CHFS, or RWLK then come over to and sign up for your free customized report today. Today's attention is focused onto the Medical Appliances and Equipment industry, which is engaged in the manufacturing of medical instruments such as dental and surgical appliances. Companies in this category tend to offer below-average dividend yields when compared to the wider market. Ahead of today's trading session, monitors the following equities: Lantheus Holdings Inc. (NASDAQ: LNTH), Intersect ENT Inc. (NASDAQ: XENT), CHF Solutions Inc. (NASDAQ: CHFS), and ReWalk Robotics Ltd (NASDAQ: RWLK). Learn more about these stocks by signing up for their free reports on at:


On Thursday, shares in North Billerica, Massachusetts headquartered Lantheus Holdings Inc. recorded a trading volume of 491,570 shares. The stock ended the session 1.80% higher at $17.00. The Company's shares have surged 97.67% on an YTD basis. The stock is trading 31.11% above its 200-day moving average. Moreover, shares of Lantheus, which develops, manufactures, and commercializes diagnostic medical imaging agents and products for the diagnosis and treatment of cardiovascular and other diseases worldwide, have a Relative Strength Index (RSI) of 49.43.

On August 23rd, 2017, Lantheus announced that it will be presenting at the Wells Fargo Securities 2017 Healthcare Conference on September 06th, 2017, at the Westin Boston Waterfront Hotel in Boston. Mary Anne Heino, President and CEO, and Jack Crowley, CFO, will participate in an analyst-led fireside chat scheduled at 11:25 a.m. ET that day. The free research report on LNTH is available at:

Intersect ENT 

Menlo Park, California headquartered Intersect ENT Inc.'s stock closed the day 0.49% lower at $30.75 with a total trading volume of 242,729 shares. The Company's shares have advanced 9.04% in the past month, 28.13% in the previous three months, and 154.13% since the start of this year. The stock is trading 7.93% and 61.80% above its 50-day and 200-day moving averages, respectively. Additionally, shares of Intersect ENT, which provides therapeutic solutions for patients with ear, nose, and throat conditions in the US, have an RSI of 60.87.

On August 01st, 2017, Intersect ENT reported financial results for Q2 ended June 30th, 2017. For Q2 2017, total revenue grew to $24.0 million, gross profit was $20.3 million, and operating expenses were $22.9 million. Cash, cash equivalents, and short-term investments totaled $100.0 million as of June 30th, 2017. The complimentary report on XENT can be downloaded at:

CHF Solutions 

Shares in Eden Prairie, Minnesota-based CHF Solutions Inc. recorded a trading volume of 255,144 shares. The stock ended yesterday's trading session 0.43% higher at $0.67. The Company's shares have advanced 9.39% in the previous three months. The stock is trading below its 50-day moving average by 6.79%. Furthermore, shares of CHF Solutions, which develops cardiac and coronary disease products primarily in the US, have an RSI of 47.64.

On August 03rd, 2017, CHF Solutions announced that it has begun the process of transitioning the manufacturing of the Aquadex FlexFlow System from an indirect subsidiary of Baxter International, Inc., a global leader in the hospital products and dialysis markets, to the Company's facility in Eden Prairie, Minnesota. The initial step, the transfer of the manufacturing assets, has been completed during the previous week. Visit us today and download our complete research report on CHFS for free at:

ReWalk Robotics 

Yokneam Ilit, Israel headquartered ReWalk Robotics Ltd's stock finished Thursday's session 8.89% higher at $1.48 with a total trading volume of 281,807 shares. The Company's shares have advanced 1.76% in the last one month and 20.45% over the previous three months. The stock is trading below its 50-day moving average by 3.47%. Additionally, shares of ReWalk Robotics, which designs, develops, and commercializes exoskeletons for wheelchair-bound individuals with mobility impairments or other medical conditions, have an RSI of 49.22.

On August 03rd, 2017, ReWalk Robotics announced its financial results for the three months ended June 30th, 2017. For Q2 2017, total revenue was $2 million; gross margin improved to 37%; total operating expenses were $6.1 million; and net loss was $6.3 million. As of June 30th, 2017, the Company had $16.3 million in cash on its balance sheet. Get free access to your technical report on RWLK at:


Daily Stock Tracker: 

Daily Stock Tracker (DST) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. DST has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below. 

DST has not been compensated; directly or indirectly; for producing or publishing this document. 


The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email Rohit Tuli, a CFA(R) charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by DST. DST is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.  


DST, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. DST, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, DST, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice. 


This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither DST nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit


        For any questions, inquiries, or comments reach out to us directly. If you're a company
         we are covering and wish to no longer feature on our coverage list contact us via
         email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at: 
        Phone number: (207)331-3313 
        Office Address: 377 Rivonia Boulevard, Rivonia, South Africa 


CFA(R) and Chartered Financial Analyst(R) are registered trademarks owned by CFA Institute.